Search

• Emergence of a new H1N1 influenza A strain (swine influenza)

  Media

  GSK is closely monitoring H1N1 strain in Mexico, US, Canada, France, Spain & New Zealand. WHO stated, situation a cause for concern.

  https://www.gsk.com/en-gb/media/press-releases/emergence-of-a-new-h1n1-influenza-a-strain-swine-influenza/

  First published: 26 April 2009

• Pandemic 2009 Influenza Update: Pandemrix™ data on co-administration with annual seasonal influenza vaccine (Fluarix®)

  Media

  The trial involves 168 adults aged over 60 years of age, and was designed to evaluate the tolerability and immunogenicity.

  https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-pandemrix-data-on-co-administration-with-annual-seasonal-influenza-vaccine-fluarix/

  First published: 09 November 2009

• GlaxoSmithKline update: influenza A (H1N1)

  Media

  GSK committed to supporting governments and health authorities around the world to respond to the emergence of the new H1N1 strain.

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-influenza-a-h1n1/

  First published: 30 April 2009

• GSK’s respiratory syncytial virus older adult vaccine candidate gains positive European Medicines Agency CHMP opinion

  Media

  Positive opinion advances GSK’s goal to provide the first vaccine to help protect older adults from respiratory syncytial virus disease

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-respiratory-syncytial-virus-older-adult-vaccine-candidate-gains-positive-european-medicines-agency-chmp-opinion/

  First published: 27 April 2023

• Pandemic (H1N1) 2009 Influenza Update: Initial results from first clinical trial of GSK’s H1N1 adjuvanted vaccine

  Media

  GlaxoSmithKline (GSK) today announced results from its first clinical trial assessing use of its pandemic (H1N1) adjuvanted vaccine.

  https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-initial-results-from-first-clinical-trial-of-gsk-s-h1n1-adjuvanted-vaccine/

  First published: 14 September 2009

• GSK welcomes key agreement to support global preparedness against pandemic influenza

  Media

  GSK welcomes agreement reached at OEWG coordinated by WHO on a Framework to support global preparedness for a future influenza pandemic.

  https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-key-agreement-to-support-global-preparedness-against-pandemic-influenza/

  First published: 18 April 2011

• Regulatory Update: GSK announces submissions for two influenza vaccines

  Media

  GSK announced today that it has submitted regulatory files for two of its influenza vaccines currently in development.

  https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-submissions-for-two-influenza-vaccines/

  First published: 05 March 2012

• US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older adult vaccine candidate

  Media

  Committee votes unanimously that the data support the effectiveness of the vaccine and 10-2 that the data support the safety of the vaccine

  https://www.gsk.com/en-gb/media/press-releases/us-fda-advisory-committee-votes-to-support-effectiveness-and-safety-of-gsk-s-rsv-older-adult-vaccine-candidate/

  First published: 01 March 2023

• GSK presents positive data for Arexvy, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons

  Media

  GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through 3 full seasons.

  https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-for-arexvy-its-rsv-vaccine-indicating-protection-over-three-rsv-seasons/

  First published: 08 October 2024

• GSK and Zhifei revise and extend strategic vaccine collaboration in China

  Media

  Shingrix collaboration extended to 2034

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-zhifei-revise-and-extend-strategic-vaccine-collaboration-in-china/

  First published: 05 December 2024